ENOV

NYSE Healthcare

Enovis Corporation Common Stock

Medical Devices

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

๐Ÿ“Š Market Data
๐ŸŽฏ Investment Strategy Scores

ENOV scores across each investment strategy. Higher is better for that strategy's goals.

High dividend yield + low volatility
๐Ÿš€ Moon Shot 89/100โ€” 0
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 83/100โ–ผ -1
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 22/100โ–ฒ +2
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿš€ Moon Shot (89/100) โ€” this strategy High growth potential (high beta + oversold).

Lowest fit among scored strategies: ๐Ÿ’ฐ Dividend Daddy (12/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find ENOV in your text

Paste any article, transcript, or post โ€” the tool will extract ENOV and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.